Senda Biosciences
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
Senda Biosciences was a Flagship Pioneering biotech company launched in October 2020 with $88 million in cash, led by CEO Guillaume Pfefer (also a CEO-Partner at Flagship). It built the first platform to leverage a universal chemical code of natural nanoparticles — proprietary particles derived from microorganisms that had co-evolved with human cells — enabling directed, repeatable deployment of payloads such as translatable RNA directly to chosen cells and tissues. The company raised about $309 million in total.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Launched
Flagship Pioneering launches Senda Biosciences with $88 million in cash, led by CEO Guillaume Pfefer.
- Merged into Sail Biomedicines
On October 19, 2023, Flagship announces that Senda Biosciences and fellow portfolio company Laronde (Endless RNA) merge to form Sail Biomedicines, combining Senda's programmable nanoparticles with Laronde's eRNA payloads to design fully programmable medicines; Sail launches with more than $700 million in combined coffers, led by Pfefer as CEO.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.